Table 3.
Characteristics of the 15 CP-CML patients whose B-cell subsets were analyzed at diagnosis (ie, prior to initiating imatinib therapy) and once CCyR was achieved on imatinib
| Patient | Age | Gender | Duration of imatinib therapy* (mo) | BCR-ABL/ABL (%)* |
|---|---|---|---|---|
| A | 50.4 | F | 34 | 0.017 |
| B | 54.8 | F | 42 | 0.014 |
| C | 37.1 | M | 23 | 0.104 |
| D | 53.6 | M | 32 | 0.338 |
| E | 44.2 | M | 20 | 0.115 |
| F | 38.0 | F | 18 | 0.619 |
| G | 35.1 | M | 41 | 0.08 |
| H | 41.5 | F | 54 | 0.003 |
| I | 46.7 | F | 25 | 0.365 |
| J | 55.9 | M | 21 | 0.003 |
| K | 59.2 | M | 21 | 0.231 |
| L | 58.1 | F | 30 | 0.017 |
| M | 56.5 | F | 35 | 0.578 |
| N | 49.6 | F | 33 | 0.005 |
| O | 27.9 | M | 19 | 0.004 |
*
Duration of treatment with imatinib when remission sample was collected.